Status:
COMPLETED
A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly
Lead Sponsor:
Janssen-Cilag International NV
Conditions:
Schizophrenia
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to explore the experience with paliperidone palmitate 3-month formulation (PP3M) treatment of participants and their corresponding physicians, nurses and carers, to unders...
Eligibility Criteria
Inclusion
- Have a diagnosis of schizophrenia (according to International Classification of Diseases \[ICD\]-10)
- Be currently receiving PP3M and have previously received 4 to 6 injections of PP3M
- Have the required language skills to participate in the online questionnaire, in the opinion of the physician
- Be able and willing to provide their informed consent for study participation
Exclusion
- Has received involuntary treatment with PP3M
- Was switched to PP3M treatment within a clinical trial
Key Trial Info
Start Date :
November 21 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 12 2019
Estimated Enrollment :
225 Patients enrolled
Trial Details
Trial ID
NCT03809325
Start Date
November 21 2018
End Date
July 12 2019
Last Update
April 27 2025
Active Locations (41)
Enter a location and click search to find clinical trials sorted by distance.
1
Chu Brugmann
Brussels, Belgium, 1020
2
Centre Médico Psychologique De Courbevoie
Asnières-sur-Seine, France, 92600
3
Centre Medico Psychologique
Cagnes-sur-Mer, France, 6800
4
Cabinet medical
Dax, France, 40100